FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323348522> ?p ?o ?g. }

• W4323348522 endingPage "755" @default.
• W4323348522 startingPage "747" @default.
• W4323348522 abstract "<h3>Abstract</h3> Background/Aim: The advent of immune checkpoint inhibitor (ICI) treatment has transformed the treatment of recurrent or metastatic head and neck cancer; however, nasopharyngeal carcinoma (NPC) has not been included in major phase III trials. The clinical outcomes of ICI for NPC in real-world practice remain to be fully elucidated. Patients and Methods: We retrospectively reviewed 23 patients with recurrent or metastatic NPC treated with nivolumab or pembrolizumab at 6 institutions from April 2017 to July 2021 and investigated the correlation of clinicopathological factors and immune-related adverse events with the effects of ICI therapy and the prognosis. Results: The objective response rate was 39.1% and the disease control rate was 78.3%. The median progression-free survival was 16.8 months and overall survival has not been reached. As with other treatment procedures, the efficacy and the prognosis tended to be better in EBER-positive cases than in EBER-negative cases. The rate of significant immune-related adverse events that necessitated discontinuation of treatment was only 4.3%. Conclusion: ICI monotherapy (e.g., nivolumab and pembrolizumab) was effective and tolerable for NPC in a real-world setting." @default.
• W4323348522 created "2023-03-08" @default.
• W4323348522 creator A5000400428 @default.
• W4323348522 creator A5007921825 @default.
• W4323348522 creator A5016107032 @default.
• W4323348522 creator A5021568645 @default.
• W4323348522 creator A5027311483 @default.
• W4323348522 creator A5052196478 @default.
• W4323348522 creator A5057184149 @default.
• W4323348522 creator A5061991532 @default.
• W4323348522 creator A5076769300 @default.
• W4323348522 creator A5076868011 @default.
• W4323348522 creator A5089831839 @default.
• W4323348522 date "2023-01-01" @default.
• W4323348522 modified "2023-10-16" @default.
• W4323348522 title "Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan" @default.
• W4323348522 cites W1202743356 @default.
• W4323348522 cites W1548083336 @default.
• W4323348522 cites W2019607817 @default.
• W4323348522 cites W2096655221 @default.
• W4323348522 cites W2512237822 @default.
• W4323348522 cites W2529484692 @default.
• W4323348522 cites W2743180529 @default.
• W4323348522 cites W2747272999 @default.
• W4323348522 cites W2753803220 @default.
• W4323348522 cites W2766816570 @default.
• W4323348522 cites W2794739281 @default.
• W4323348522 cites W2889548218 @default.
• W4323348522 cites W2890100090 @default.
• W4323348522 cites W2915842420 @default.
• W4323348522 cites W2945697541 @default.
• W4323348522 cites W2986633517 @default.
• W4323348522 cites W3033152242 @default.
• W4323348522 cites W3047406790 @default.
• W4323348522 cites W3082336638 @default.
• W4323348522 cites W3100953153 @default.
• W4323348522 cites W3107738233 @default.
• W4323348522 cites W3112907068 @default.
• W4323348522 cites W3124559501 @default.
• W4323348522 cites W3130630215 @default.
• W4323348522 cites W3189017418 @default.
• W4323348522 cites W3196164298 @default.
• W4323348522 cites W4200491789 @default.
• W4323348522 cites W4211017340 @default.
• W4323348522 cites W4220747055 @default.
• W4323348522 cites W4312018944 @default.
• W4323348522 doi "https://doi.org/10.21873/invivo.13137" @default.
• W4323348522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36881083" @default.
• W4323348522 hasPublicationYear "2023" @default.
• W4323348522 type Work @default.
• W4323348522 citedByCount "0" @default.
• W4323348522 crossrefType "journal-article" @default.
• W4323348522 hasAuthorship W4323348522A5000400428 @default.
• W4323348522 hasAuthorship W4323348522A5007921825 @default.
• W4323348522 hasAuthorship W4323348522A5016107032 @default.
• W4323348522 hasAuthorship W4323348522A5021568645 @default.
• W4323348522 hasAuthorship W4323348522A5027311483 @default.
• W4323348522 hasAuthorship W4323348522A5052196478 @default.
• W4323348522 hasAuthorship W4323348522A5057184149 @default.
• W4323348522 hasAuthorship W4323348522A5061991532 @default.
• W4323348522 hasAuthorship W4323348522A5076769300 @default.
• W4323348522 hasAuthorship W4323348522A5076868011 @default.
• W4323348522 hasAuthorship W4323348522A5089831839 @default.
• W4323348522 hasBestOaLocation W43233485221 @default.
• W4323348522 hasConcept C121608353 @default.
• W4323348522 hasConcept C126322002 @default.
• W4323348522 hasConcept C143998085 @default.
• W4323348522 hasConcept C197934379 @default.
• W4323348522 hasConcept C203014093 @default.
• W4323348522 hasConcept C2777701055 @default.
• W4323348522 hasConcept C2778715236 @default.
• W4323348522 hasConcept C2778997737 @default.
• W4323348522 hasConcept C2780030458 @default.
• W4323348522 hasConcept C2780057760 @default.
• W4323348522 hasConcept C509974204 @default.
• W4323348522 hasConcept C71924100 @default.
• W4323348522 hasConcept C8891405 @default.
• W4323348522 hasConceptScore W4323348522C121608353 @default.
• W4323348522 hasConceptScore W4323348522C126322002 @default.
• W4323348522 hasConceptScore W4323348522C143998085 @default.
• W4323348522 hasConceptScore W4323348522C197934379 @default.
• W4323348522 hasConceptScore W4323348522C203014093 @default.
• W4323348522 hasConceptScore W4323348522C2777701055 @default.
• W4323348522 hasConceptScore W4323348522C2778715236 @default.
• W4323348522 hasConceptScore W4323348522C2778997737 @default.
• W4323348522 hasConceptScore W4323348522C2780030458 @default.
• W4323348522 hasConceptScore W4323348522C2780057760 @default.
• W4323348522 hasConceptScore W4323348522C509974204 @default.
• W4323348522 hasConceptScore W4323348522C71924100 @default.
• W4323348522 hasConceptScore W4323348522C8891405 @default.
• W4323348522 hasIssue "2" @default.
• W4323348522 hasLocation W43233485221 @default.
• W4323348522 hasLocation W43233485222 @default.
• W4323348522 hasLocation W43233485223 @default.
• W4323348522 hasOpenAccess W4323348522 @default.
• W4323348522 hasPrimaryLocation W43233485221 @default.
• W4323348522 hasRelatedWork W2751400660 @default.
• W4323348522 hasRelatedWork W2785808209 @default.

• next